Gastrointestinal symptoms associated with enteric-coated sulfasalazine (Azulfidine EN tablets)

Okubo, Susumu; Nakatani, Ko; Nishiya, Koji

doi:10.3109/s101650200039

Cited by 6 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Similarly, we find that sulfasalazine (a drug used to treat rheumatoid arthritis and ulcerative) causes vomiting. This finding is supported by [41], which reports that 64 out of 152 people developed adverse reactions due to this drug, and 19 out of that 64 had vomiting. Finally, our model predicts halcinonide to cause hypertension.…”

Section: Discussionsupporting

confidence: 53%

DeepSide: A Deep Learning Approach for Drug Side Effect Prediction

Uner¹,

Kuru²,

Cinbiş³

et al. 2023

IEEE/ACM Trans. Comput. Biol. and Bioinf.

View full text Add to dashboard Cite

Drug failures due to unforeseen adverse effects at clinical trials pose health risks for the participants and lead to substantial financial losses. Side effect prediction algorithms have the potential to guide the drug design process. LINCS L1000 dataset provides a vast resource of cell line gene expression data perturbed by different drugs and creates a knowledge base for context specific features. The state-of-the-art approach that aims at using context specific information relies on only the high-quality experiments in LINCS L1000 and discards a large portion of the experiments. In this study, our goal is to boost the prediction performance by utilizing this data to its full extent. We experiment with 5 deep learning architectures. We find that a multi-modal architecture produces the best predictive performance among multi-layer perceptron-based architectures when drug chemical structure (CS), and the full set of drug perturbed gene expression profiles (GEX) are used as modalities. Overall, we observe that the CS is more informative than the GEX. A convolutional neural network-based model that uses only SMILES string representation of the drugs achieves the best results and provides 13:0% macro-AUC and 3:1% micro-AUC improvements over the state-of-the-art. We also show that the model is able to predict side effect-drug pairs that are reported in the literature but was missing in the ground truth side effect dataset. DeepSide is available at http://github.com/OnurUner/DeepSide.

show abstract

Section: Discussionsupporting

confidence: 53%

DeepSide: A Deep Learning Approach for Drug Side Effect Prediction

Uner¹,

Kuru²,

Cinbiş³

et al. 2023

IEEE/ACM Trans. Comput. Biol. and Bioinf.

View full text Add to dashboard Cite

show abstract

“…A total of 62 cases of pruritus were reported, with incidences of pruritus in RA patients varying from 0.8% ('uncommon') to 25.0% ('very common'). Mucositis (including mouth ulceration and stomatitis) associated with the use of sulfasalazine is mentioned with an incidence 'unknown' in the SmPC, but is a well-known ADR in literature [35]. A retrospective study of Okubo et al [2002, 35] reported an estimated incidence of 5.9% (n = 9), implying the incidence is 'common'.…”

Section: Discussionmentioning

confidence: 99%

Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients

Giraud

Jessurun

Hunsel

et al. 2020

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Objectives: To describe the cumulative incidences of adverse drug reactions (ADRs) associated with disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients from real-world data (RWD), using the DREAM-RA registry, and to compare these with incidence frequencies mentioned in the Summary of Product Characteristics (SmPC). Methods: All ADRs in patients with recorded use of adalimumab, etanercept, hydroxychloroquine, leflunomide, oral and subcutaneous methotrexate, and sulfasalazine from a single center participating in the DREAM-RA registry (n = 1,098 patients) that were directly sent to the Netherlands Pharmacovigilance Center Lareb were assessed. Cumulative incidences were calculated, described and compared to the most recently revised SmPCs. Results: In total, 14 ADRs (≥5 case reports) associated with the use of one of the included DMARDs were reported with a higher estimated cumulative incidence compared to the SmPC. For hydroxychloroquine and sulfasalazine, 5 ADRs (≥5 case reports) mentioned with an 'unknown' incidence in the SmPC were reported as 'common' in this study. Conclusions: Although ADR data in the DREAM-RA registry were partly comparable with data in the SmPCs, RWD from this patient registry provided an added value to the currently available information on the incidences of ADRs associated with DMARDs in RA patients as described in SmPCs.

show abstract

“…They resolve with discontinuation or dose reduction and are better tolerated with the use of an enteric-coated formulation. 87,88…”

Section: Sulfasalazinementioning

confidence: 99%

Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients

Betancourt¹,

Biehl²,

Katz³

et al. 2018

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Providing safe and effective pharmacotherapy to geriatric patients with rheumatologic disorders is challenging. Multidisciplinary care involving rheumatologists, primary care physicians, and other specialties can optimize benefit and reduce adverse outcomes. Oral disease-modifying antirheumatic drugs, including methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and the small molecule inhibitors tofacitinib and apremilast have distinctive monitoring requirements and specific adverse reaction profiles. This article provides clinically relevant pearls for use of these interventions in older patients.

show abstract

Gastrointestinal symptoms associated with enteric-coated sulfasalazine (Azulfidine EN tablets)

Cited by 6 publications

References 5 publications

DeepSide: A Deep Learning Approach for Drug Side Effect Prediction

DeepSide: A Deep Learning Approach for Drug Side Effect Prediction

Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients

Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients

Contact Info

Product

Resources

About